Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of mesutoclax + azacitidine versus venetoclax + azacitidine in newly diagnosed AML patients who are elderly or unfit for intensive chemotherapy
CTR20263691Phase 3Active
- Sponsor
- Innovent Biologics
- Start
- Sep 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of mesutoclax, azacitidine, venetoclax in acute myeloid leukemia (AML), sponsored by Innovent Biologics. Started Sep 2026; status: active.
02
Drugs
mesutoclaxazacitidinevenetoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on CTR20263691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263691.